Foros de Conocimiento
medtronic PRODUCTOS
boston_scientific PRODUCTOS
TERUMO PRODUCTOS
Biotronik PRODUCTOS
Sirtex PRODUCTOS
Striker Neurovascular PRODUCTOS
BIOSENSORS PRODUCTOS

NOTICIAS


26 septiembre 2012

Renal denervation may be cost-effective for resistant hypertension

Cardiovascular NEWS

A study published in the Journal of the American College of Cardiology, based on data from the Symplicity HTN-2 trial, suggests that renal denervation may be a cost-effective method of managing resistant hypertension and may result in a reduction in cardiovascular morbidity and mortality in the long term.

19 septiembre 2012

Really, how safe is renal denervation?

Interventional NEWS

Electrophysiologist Clemens Jilek, German Heart Centre Munich, Germany, presented on how the technique of renal ablation could affect the renal artery and how renal denervation could be improved at CIRSE 2012 (15–19 September, Lisbon, Portugal) in a presentation titled “How bad is radiofrequency for the renal arteries?”

19 septiembre 2012

Leading interventionalists hail new certificate at CIRSE 2012

Interventional NEWS

Key members of the Society of Interventional Radiology (SIR) have praised a new dual certificate for diagnostic radiology and interventional radiology, saying it recognises interventional radiology as a “a new form of medicine”.

13 septiembre 2012

Interventional radiology in the USA now a primary specialty in medicine

Interventional NEWS

On 11 September, the American Board of Medical Specialties (ABMS) recognised the unique interventional radiology skill set with the new dual certificate in interventional radiology and diagnostic radiology. The Society of Interventional Radiology (SIR) has hailed the affirmation of the specialty s role in patient care.

06 septiembre 2012

Use of standardised checklists improves patient safety in interventional radiology

Interventional NEWS

A recent clinical investigation from The Netherlands, published in the journal Cardiovascular and Interventional Radiology (CVIR), has revealed that the use of a validated comprehensive patient safety checklist in interventional radiology in a tertiary referral centre led to a significant decrease in process deviations and procedure postponements.

04 septiembre 2012

Renal stenting lowers blood pressure in patients with severe hypertension, HERCULES trial shows

Cardiovascular NEWS

Patients with uncontrolled renovascular hypertension saw a significant improvement in their blood pressure with renal artery stenting. The multicentre HERCULES trial, evaluating the safety and effectiveness of the RX Herculink Elite Stent (Abbott Vascular), found that patients with higher blood pressure levels at baseline had the most dramatic reduction in blood pressure following intervention. Results have been published in the September issue of Catheterization and Cardiovascular Interventions.

03 septiembre 2012

The future of renal denervation rests on selecting the right patient

Cardiovascular NEWS

“We need to be very careful not to kill a promising technology with incorrect patient selection,” Pierre-François Plouin, Paris, France, warned delegates at the EuroPCR Great Debate 2012 on renal denervation. In the debate, Plouin and four other experts in interventional cardiology, interventional radiology and nephrology agreed that identifying the right group of patients is key for the future of the technique. The group also discussed patient compliance to medical therapy, clinical data associated with the procedure and the balance between risk and benefit.

30 agosto 2012

FDA clears AngioDynamics BioFlo peripherally inserted central catheters

Interventional NEWS

The US Food and Drug Administration (FDA) has granted 510(k) clearance to AngioDynamics for its BioFlo peripherally inserted central catheters (PICCs) with Endexo technology designed to reduce the accumulation of catheter-related thrombus on, and in, the catheter.

31 agosto 2012

EnligHTN safe and effective for the treatment of resistant hypertension

Interventional NEWS

Results from the EnligHTN I trial have shown that the EnligHTN renal denervation system (St Jude Medical) is safe and effective for the treatment of resistant hypertension. Data released during the ESC Congress 2012 demonstrated that on average patients with resistant hypertension experienced a rapid systolic blood pressure reduction of 28 mmHg points after 30 days that remained stable with a reduction of 27 mmHg points three months after treatment.

Utilizamos cookies propias para el correcto funcionamiento del sitio web y mejorar nuestros servicios. Pulse el botón Aceptar todas para aceptar su uso. Puede cambiar la configuración u obtener más información en nuestra Política de cookies o pulsando Modificar configuración.